Literature DB >> 6587154

Effect of five antineoplastic agents on tumor xenografts with different growth rates.

J Mattern, K Wayss, M Volm.   

Abstract

The effects of cyclophosphamide (Cy), doxorubicin (Dx), cisplatin (DDP), melphalan (L-PAM), and vincristine (VCR) on various human and animal tumor lines with different growth rates, growing as xenografts in NMRI (nu/nu) mice, were studied. Two types of response were observed: For Cy and Dx, the response of the xenografts was negatively correlated with tumor volume doubling time (TD), indicating that rapidly growing tumors were more sensitive to these drugs than were slowly growing tumors. For DDP, L-PAM, and VCR, the effects were positively correlated with the TD, indicating that slowly growing tumors were more sensitive to these drugs than rapidly growing tumors. The data are discussed in relation to the effects of the drugs on proliferating and nonproliferating cells obtained with other cell lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587154

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Predicting chemosensitivity of tumors.

Authors:  J Mattern; K Wayss; M Volm
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

Review 2.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

3.  Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis.

Authors:  Tiziana Genovese; Rosalba Siracusa; Ramona D'Amico; Marika Cordaro; Alessio Filippo Peritore; Enrico Gugliandolo; Rosalia Crupi; Angela Trovato Salinaro; Emanuela Raffone; Daniela Impellizzeri; Salvatore Cuzzocrea; Roberta Fusco; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

4.  In vivo characterization of a doxorubicin resistant B16 melanoma cell line.

Authors:  F Formelli; C Rossi; R Supino; G Parmiani
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.